OBJECTIVE—To study the prevalence of and risk factors for abnormal glucose tolerance in transfusion-dependent β-thalassemic patients.

RESEARCH DESIGN AND METHODS—A total of 89 transfusion-dependent β-thalassemic patients were interviewed. Diabetes was previously diagnosed in 14 of them. In the remaining 75 patients, 68 participated in an oral glucose tolerance test. Potential risk factors were identified using the independent t test, χ2 test, and Fisher’s exact test. Logistic regression analysis was used to select the independent risk factors that best predicted abnormal glucose tolerance. A two-tailed P value of <0.05 was considered to be statistically significant.

RESULTS—The prevalence of impaired glucose tolerance was 8.5% (7 of 82) and that of diabetes was 19.5% (16 of 82). Presentation with diabetic ketoacidosis was 31.1% (5 of 16). The risk factors for abnormal glucose tolerance found in transfusion-dependent β-thalassemic patients were serum ferritin concentration and hepatitis C infection.

CONCLUSIONS—The interaction of iron overload and hepatitis C infection worsened the prognosis of thalassemic patients. Aggressive iron-chelation therapy as well as prevention and treatment of hepatitis C infection should be mandatory in managing glucose homeostasis in transfusion-dependent β-thalassemic patients in Taiwan.

β-Thalassemia major, first described by Cooley and Lee (1), is a serious disease generally diagnosed within the first year of life on the basis of presentations with anemia, hepatosplenomegaly, growth retardation, jaundice, and bone changes. The cause is a genetic mutation that reduces or even halts the synthesis of β-globin chains. Before the institution of regular blood transfusion, patients with β-thalassemia major died during the first few years of life from congestive heart failure or other complications resulting from chronic anemia (2). Transfusion and iron-chelation therapy have prolonged and improved the quality of life in patients with this disease. The improvement was mainly due to the decrease in mortality from heart failure (3,4). Such a treatment, however, leads to chronic iron overload and frequently to endocrine complications, especially the development of diabetes (5,6,7). Prevalence has been reported to range from 2.3 to 24% (8,9,10,11), and risk factors for diabetes in patients with β-thalassemia major have been suggested to include age, increased amount of blood transfusion, serum ferritin level, compliance with iron-chelation therapy, family history of diabetes, hepatitis viruses, and pubertal status (8,9,10,11,12). Before our study, the prevalence and risk factors for abnormal glucose tolerance in patients with blood-transfused β-thalassemia in Taiwan were unknown; the present study was designed to fill this gap.

Patient enrollment and evaluation

Blood-transfused patients with β-thalassemia were recruited between January and May 2000 from the thalassemia clinics of National Taiwan University Hospital and Tao-Yuan General Hospital, Department of Health, which are the main hospitals in Taiwan that care for thalassemic patients. Those eligible for study were ≥2 years of age and were receiving frequent transfusions (15 ml packed erythrocytes per kg body wt given every 2–3 weeks to keep their hemoglobin level at a minimum of 10 g/dl before each transfusion). Taken at least 5 days each week, the dose of iron-chelating agent deferoxamine prescribed was 30–50 mg per kg body wt per day. The drug was given by subcutaneous infusion overnight for 8–12 h. There were 89 patients (demographic data are shown in Table 1) who met the criteria and consented to participate (i.e., they agreed to answer the questionnaire). Of the 89 patients, 14 were diagnosed with diabetes before the present study. In the remaining 75 patients, 68 were tested for blood glucose. All patients were interviewed and filled out standardized questionnaires during the first visit of the study, and their medical histories were obtained from the hospital files. This information included the following: age, sex, height, body weight, pubertal status according to Tanner’s classification, age at the first blood transfusion, duration of blood transfusion, age at the start of iron-chelation therapy, duration of iron-chelation therapy, compliance with iron-chelation therapy, serum ferritin level within 6 months, existence of hepatitis B surface antigen, existence of hepatitis C antibody, previous splenectomy, family history of diabetes, and previous bone marrow transplantation. The compliance with deferoxamine chelation therapy was assessed as good (≥5 deferoxamine infusions per week) in 59 subjects and poor (<4 infusions per week) in 23. A complete family history of diabetes noted in first-degree relatives and siblings was collected.

Definitions and oral glucose tolerance test

In this study, we used the World Health Organization’s definition of diabetes (13), which holds that subjects with regular treatment of diabetes are considered diabetic. If patients were not diabetic, an oral glucose tolerance test (OGTT) was performed in the morning after an overnight fast, as recommended by the National Diabetes Data Group (14). Glucose was ingested in a dose of 1.75 g/kg up to a maximum of 75 g, and blood samples were obtained at 0 and 120 min for measurement of plasma glucose. Patients ≥10 years of age were evaluated by a glucose tolerance test, whereas patients <10 years of age were evaluated by either a glucose tolerance test or a fasting glucose test, with the choice of test depending on the patients and their parents (15). An abnormal fasting glucose test result was followed by the administration of a glucose tolerance test (16).

Statistical analysis

Differences between patients with and without abnormal glucose tolerance were tested with the independent t test, χ2 test, and Fisher’s exact test to identify the potential risk factors. In addition, multivariate analysis was performed using the stepwise logistic regression analysis to select the independent risk factors that best predicted abnormal glucose tolerance. A two-tailed P value of <0.05 was considered to be statistically significant.

Study population

During the study period, 89 patients (41 male and 48 female subjects) underwent regular blood transfusion in the thalassemia clinics of National Taiwan University Hospital and Tao-Yuan General Hospital, Department of Health. The age distribution of the patients is shown in Fig. 1. Although prenatal diagnosis for thalassemia had been initiated in 1993 in Taiwan, there were nonetheless 10 patients with thalassemia in this study who were born after 1994. These cases probably resulted from a new genetic mutation and poor coverage at the start of the prenatal screening program. There were also three “thalassemia intermedia” patients who were 7, 14, and 18 years of age at the start of blood transfusion. Of 82 patients, 59 (72.0%) had normal glucose tolerance, 7 (8.5%) had impaired glucose tolerance (IGT), and 16 (19.5%) had diabetes; 14 of the 16 diabetic subjects had been diagnosed previously. The characteristics of these different groups are shown in Table 2.

IGT

All seven patients with IGT were diagnosed on the basis of OGTT results. Mean age at diagnosis was 16.6 ± 4.9 years, mean age at the start of blood transfusion was 9.3 months (range 2–14 months), and mean age at the start of iron-chelation therapy was 9.6 years (4–24 years). The compliance was good in only two patients (28.6%). The serum ferritin concentration at the time of diagnosis ranged from 2,000 to 9,549 μg/l (mean 5,827.6). Three patients (42.9%) had hepatitis C infection, and none had hepatitis B infection. Splenectomy was performed in two patients (28.6%). No patients received bone marrow transplantation. Two patients (28.6%) had a family history of diabetes.

Diabetes

Of the 16 diabetic patients, 2 were diagnosed during the study and 14 were diagnosed previously. Mean age at the diagnosis was 17.4 years (range 7–24). Data about the manifestation of diabetes, available in 15 of 16 patients, indicated that diabetic ketoacidosis was the initial manifestation in 5 patients (31.1%) and asymptomatic hyperglycemia was the initial diagnosis in 11 patients (68.9%). Mean age at the start of blood transfusion was 5.75 months (1,2,3,4,5,6,7,8,9,10,11,12), and it was 9.8 years (4–19) at start of iron-chelation therapy. The compliance was good in nine patients (56.3%). The serum ferritin concentration, available in 13 patients at the time of diagnosis, ranged from 1,180 to 13,500 μg/l (mean 5,299.6). Of the 15 patients for whom data on viral hepatitis were available, none had hepatitis B, and 9 (56.3%) had hepatitis C infection. Eight patients (50%) underwent splenectomy and three (18.8%) received bone marrow transplantation. Four patients (25%) had a positive family history of diabetes.

Relevance of the OGTT criterion from the new standards of the American Diabetes Association

Blood glucose levels of patients newly diagnosed with IGT and diabetes are shown in Table 3. In the patients with IGT, fasting glucose levels of two patients (28.6%) were <110 mg/dl; in patients with diabetes, the fasting glucose level of one patient (50%) was <126 mg/dl. We therefore consider the American Diabetes Association (ADA) criterion (17) to be unsuitable for diagnosis of IGT or diabetes in this rare disease group (18).

Risk factors for abnormal glucose tolerance

After combining the patients with IGT and those with diabetes, we determined which patients had abnormal glucose tolerance levels. We then grouped the patients into those having normal and those having abnormal glucose tolerance. The risk factors associated with abnormal glucose tolerance were assessed (Table 4). Univariate analyses showed the following variables to be significantly associated with abnormal glucose tolerance: age of patient, height, body weight, age at the first transfusion, duration of blood transfusion, age at the start of iron-chelation therapy, compliance with iron-chelation therapy, serum ferritin concentration, hepatitis C infection, and previous splenectomy. These variables were included in the stepwise logistic regression. After adjustment for confounding factors, serum ferritin concentration (odds ratio [OR] 1.0005, P = 0.006) and hepatitis C infection (OR 3.8343, P = 0.0491) were identified as independent risk factors for abnormal glucose tolerance (Table 5).

Thalassemia is a major health concern in Taiwan; the carrier rate of β-thalassemia is at least 1.1% (19,20). The Department of Health of Taiwan has had a national thalassemia-major screening program since 1993 (21). Nevertheless, 10 children with thalassemia major were born after 1994. Consequently, the efficacy of prenatal screening programs in Taiwan is under scrutiny.

This study is the first to report the relationship between glucose tolerance and blood-transfused β-thalassemia in Taiwan. Adequate iron-chelation therapy can prevent complications, including diabetes (22,23,24,25). Serum ferritin concentration (OR 1.0005, P = 0.006), a marker for hepatic iron concentration, was found to be an independent risk factor in this study. Serum ferritin has been considered to be a component of insulin resistance syndrome in epidemiological studies (26). Our results in this rare disease group lend further support to this viewpoint.

Studies have indicated that when the serum ferritin level is <2,500 μg/l, the incidence of diabetes is reduced (15,22,23). By contrast, we found that three patients with diabetes and one patient with IGT had serum ferritin levels of 1,180, 1,475, 1,580, and 2,000 μg/l, respectively. Although serum ferritin plays an important role in the genesis of insulin resistance, we believe that the development of diabetes might be complicated by other conditions.

Diabetes has been observed to develop shortly after an episode of acute viral hepatitis in thalassemic patients (11), and chronic hepatitis C infection was considered to have a diabetogenic effect (27). None of our patients had acute hepatitis, but in our patients with chronic infection, hepatitis C was found to be an independent risk factor for abnormal glucose tolerance (OR 3.8343, P = 0.0491). Because iron-induced hepatic damage is exacerbated by infection with hepatitis C virus (28,29), hepatic dysfunction may be the most important cause for the development of insulin resistance (12,15,21,30) and abnormal glucose tolerance. Therefore, the interplay of iron burden and hepatitis C may be the determining factor in the development of abnormal glucose tolerance. We believe that age and duration of blood transfusion merely determine the total amount of blood transfused. When that amount increases, the possibility of iron overload and infection with hepatitis C virus is increased.

It is still unclear whether diabetes in β-thalassemia major is related to genetic factors (6,10,12,15,32,33). We did not demonstrate that family history was a risk factor in our patient group.

Many drugs used for bone marrow transplantation may be diabetogenic, but our data showed that previous bone marrow transplantation (33,34,35) was not a risk factor in the development of abnormal glucose tolerance.

The mechanism of abnormal glucose homeostasis in patients with β-thalassemia major is still unknown but is attributed mainly to insulin deficiency resulting from the toxic effects of iron deposited in the pancreas (5,6,31) and from insulin resistance (12,15,28). Insulin resistance may come from iron deposition in both liver (where iron deposits may interfere with insulin’s ability to suppress hepatic glucose production) and muscle (where iron deposits may decrease glucose uptake because of muscle damage) (12). Persistent insulin resistance along with a progressive reduction in circulating insulin levels may lead to glucose intolerance and overt diabetes (36).

Early identification of thalassemic patients with IGT has decreased presentations with diabetic ketoacidosis, but these presentations remain as high as 31.1% in Taiwan, according to this study. As a result, physicians caring for patients with thalassemia major should be particularly alert to the possibility of diabetes. Because not all of the patients with thalassemia major could be correctly diagnosed by fasting glucose alone (18), we preferred to use OGTT rather than the guidelines of the ADA (17) for the diagnosis of abnormal glucose tolerance in thalassemic patients.

In conclusion, we found that serum ferritin concentration and hepatitis C infection are risk factors of abnormal glucose tolerance in patients with blood-transfused β-thalassemia. Aggressive iron-chelation therapy and prevention and treatment of hepatitis C infection are now the most important issues in managing glucose homeostasis in transfusion-dependent β-thalassemic patients in Taiwan.

Figure 1 —

Age distribution of transfusion-dependent β-thalassemic patients. The Department of Health of Taiwan has had a national thalassemia-major screening program since 1993. Nevertheless, 10 children with thalassemia major were born after 1994.

Figure 1 —

Age distribution of transfusion-dependent β-thalassemic patients. The Department of Health of Taiwan has had a national thalassemia-major screening program since 1993. Nevertheless, 10 children with thalassemia major were born after 1994.

Close modal
Table 1 —

Demographic characteristics of 89 transfusion-dependent β-thalassemic patients

Patient characteristics
Sex 
 Male 41 
 Female 48 
Age (years) 14.8 ± 6.9 
Height (cm) 140.7 ± 19.7 
Body weight (kg) 37.2 ± 12.7 
Mean age at first blood transfusion (months) 15.1 ± 30.6* 
Mean age at start of iron-chelation therapy (years) 6.8 ± 5.4 
Number of patients with good compliance 64 (71.9) 
Ferritin (μg/l) 3701.3 ± 2530.7 
Hepatitis B infection 2 (2.2) 
Hepatitis C infection 26 (29.2) 
Splenectomy 18 (20.2) 
Family history of diabetes 27 (30.3) 
Tanner’s stage 
 1 51 (58) 
 2 14 (15.9) 
 3 10 (11.4) 
 4 5 (5.7) 
 5 8 (9.1) 
Patient characteristics
Sex 
 Male 41 
 Female 48 
Age (years) 14.8 ± 6.9 
Height (cm) 140.7 ± 19.7 
Body weight (kg) 37.2 ± 12.7 
Mean age at first blood transfusion (months) 15.1 ± 30.6* 
Mean age at start of iron-chelation therapy (years) 6.8 ± 5.4 
Number of patients with good compliance 64 (71.9) 
Ferritin (μg/l) 3701.3 ± 2530.7 
Hepatitis B infection 2 (2.2) 
Hepatitis C infection 26 (29.2) 
Splenectomy 18 (20.2) 
Family history of diabetes 27 (30.3) 
Tanner’s stage 
 1 51 (58) 
 2 14 (15.9) 
 3 10 (11.4) 
 4 5 (5.7) 
 5 8 (9.1) 

Data are n, means ± SD, or n (%). Number (n) of patients is given when the variable concerned is not measured in all patients.

*

Mean age at first blood transfusion in the normal glucose tolerance group was influenced by the ages of three patients with thalassemia intermedia.

Table 2 —

Characteristics of 82 transfusion-dependent β-thalassemic patients classified by the results of the OGTT

Patient characteristicsNormalIGTDiabetes
n 59 16 
Sex 
 Male 31 
 Female 28 
Percentage (%) 72 8.5 19.5 
Age (years) 13.0 ± 6.2 16.6 ± 4.9 17.4 ± 4.1 
Age range (years) 3–29 12–27 7–24 
Mean age at first blood transfusion (months) 19.8 ± 36.6* 9.3 ± 4.1 5.75 ± 3.2 
Mean age at the start of iron-chelation therapy (years) 5.8 ± 5.4 9.6 ± 6.6 9.8 ± 4.4 
Number of patients with good compliance 48 (81.4) 2 (28.6) 9 (56.3) 
Ferritin (μg/l) 3,074 ± 1,876.7 5,827.6 ± 2,522.6 5,299.6 ± 3,678.4 
Hepatitis B infection 2 (3.4) 
Hepatitis C infection 12 (20.3) 3 (42.9) 9 (56.3) 
Splenectomy 8 (13.6) 2 (28.6) 8 (50) 
Family history of diabetes 21 (35.6) 2 (28.6) 4 (25) 
Previous bone marrow transplantation 6 (10.2) 3 (18.8) 
Patient characteristicsNormalIGTDiabetes
n 59 16 
Sex 
 Male 31 
 Female 28 
Percentage (%) 72 8.5 19.5 
Age (years) 13.0 ± 6.2 16.6 ± 4.9 17.4 ± 4.1 
Age range (years) 3–29 12–27 7–24 
Mean age at first blood transfusion (months) 19.8 ± 36.6* 9.3 ± 4.1 5.75 ± 3.2 
Mean age at the start of iron-chelation therapy (years) 5.8 ± 5.4 9.6 ± 6.6 9.8 ± 4.4 
Number of patients with good compliance 48 (81.4) 2 (28.6) 9 (56.3) 
Ferritin (μg/l) 3,074 ± 1,876.7 5,827.6 ± 2,522.6 5,299.6 ± 3,678.4 
Hepatitis B infection 2 (3.4) 
Hepatitis C infection 12 (20.3) 3 (42.9) 9 (56.3) 
Splenectomy 8 (13.6) 2 (28.6) 8 (50) 
Family history of diabetes 21 (35.6) 2 (28.6) 4 (25) 
Previous bone marrow transplantation 6 (10.2) 3 (18.8) 

Data are n, means ± SD or n (%), unless otherwise indicaetd.

*

Mean age at first blood transfusion in the normal glucose tolerance group was influenced by the age of three patients with thalassemia intermedia.

Table 3 —

Blood glucose levels of patients with IGT and diabetes diagnosed by OGTT

NumberFasting glucose (mg/dl)2-h glucose (mg/dl)
IGT 
 1 122 181 
 2 121 182 
 3 119 150 
 4 94 140 
 5 111 175 
 6 124 177 
 7 93 148 
Diabetes 
 1 114 244 
 2 127 216 
NumberFasting glucose (mg/dl)2-h glucose (mg/dl)
IGT 
 1 122 181 
 2 121 182 
 3 119 150 
 4 94 140 
 5 111 175 
 6 124 177 
 7 93 148 
Diabetes 
 1 114 244 
 2 127 216 
Table 4 —

Correlation of patient characteristics with the presence or absence of glucose tolerance by univariate analysis

Patient characteristicsNormal GTAbnormal GTP
Sex 
 Male 31  9 NS 
 Female 28 14 NS 
Age (years) 13.0 ± 6.2 17.2 ± 4.3 0.000 
Height (cm) 136.8 ± 21.5 150.0 ± 10.4 0.006 
Body weight (kg) 34.5 ± 13.6 42.8 ± 6.9 0.008 
Mean age at first blood transfusion (months) 19.8 ± 36.6* 6.8 ± 3.8 NS 
Mean age of start of iron-chelation therapy (years) 5.8 ± 5.4 9.7 ± 5.1 0.004 
Number of patients with good compliance 48 (81.4) 11 (47.8) 0.002 
Ferritin (μg/l) 3,074.6 ± 1,876.7 5,484.4 ± 3,259.1 0.000 
Hepatitis B infection 2 (3.4) NS 
Hepatitis C infection 12 (20.3) 12 (52.2) 0.003 
Splenectomy 8 (13.6) 10 (43.5) 0.003 
Diabetes history 21 (35.6) 6 (26.1) NS 
Number at Tanner’s stage 
 1 35 (59.3) 13 (56.5) NS 
 2 6 (10.2) 7 (30.4) NS 
 3 7 (11.9) 2 (8.7) NS 
 4 5 (8.5) NS 
 5 6 (10.2) 1 (4.3) NS 
Patient characteristicsNormal GTAbnormal GTP
Sex 
 Male 31  9 NS 
 Female 28 14 NS 
Age (years) 13.0 ± 6.2 17.2 ± 4.3 0.000 
Height (cm) 136.8 ± 21.5 150.0 ± 10.4 0.006 
Body weight (kg) 34.5 ± 13.6 42.8 ± 6.9 0.008 
Mean age at first blood transfusion (months) 19.8 ± 36.6* 6.8 ± 3.8 NS 
Mean age of start of iron-chelation therapy (years) 5.8 ± 5.4 9.7 ± 5.1 0.004 
Number of patients with good compliance 48 (81.4) 11 (47.8) 0.002 
Ferritin (μg/l) 3,074.6 ± 1,876.7 5,484.4 ± 3,259.1 0.000 
Hepatitis B infection 2 (3.4) NS 
Hepatitis C infection 12 (20.3) 12 (52.2) 0.003 
Splenectomy 8 (13.6) 10 (43.5) 0.003 
Diabetes history 21 (35.6) 6 (26.1) NS 
Number at Tanner’s stage 
 1 35 (59.3) 13 (56.5) NS 
 2 6 (10.2) 7 (30.4) NS 
 3 7 (11.9) 2 (8.7) NS 
 4 5 (8.5) NS 
 5 6 (10.2) 1 (4.3) NS 

Data are n, means ± SD, or n (%). Number (n) of patients is given when the variable concerned is not measured in all patients. GT, glucose tolerance.

*

Mean age at first blood transfusion in the normal GT group was influenced by the ages of three patients with thalassemia intermedia.

Table 5 —

Analysis by logistic regression of the risk factors for abnormal glucose tolerance in transfusion-dependent β-thalassemic patients

VariableβSEOR (95% CI)P
Hepatitis C infection 1.3440 0.6829 1.0005 (1.0055–14.5412) 0.0491 
Ferritin 0.0005 0.0001 3.8343 (1.0003–1.0007) 0.0006 
VariableβSEOR (95% CI)P
Hepatitis C infection 1.3440 0.6829 1.0005 (1.0055–14.5412) 0.0491 
Ferritin 0.0005 0.0001 3.8343 (1.0003–1.0007) 0.0006 
1
Cooley TB, Lee P: A series of cases of splenomegaly in children with anemia and peculiar bone changes.
Trans Am Pediatr Soc
37
:
29
–30,
1925
2
Giardini C, Lucarelli G: Bone marrow transplantation in the treatment of thalassemia.
Curr Opin Hematol
1
:
170
–176,
1994
3
Zurlo MG, De Stefano P, Borgna-Pignatti C, Di Palma A, Pica A, Melevendi C, Di Gregorio F, Burattini MG, Terzoli S: Survival and causes of death in thalassemia major.
Lancet
2
:
27
–30,
1989
4
Borgna-Pignatti C, Rugolloto S, De Stefano P, Pica A, Di Gregorio F, Gamberini MR, Sabato V, Melevendi C, Cappellini MD, Verlato G: Survival and disease complications in thalassemia major.
Ann N Y Acad Sci
850
:
227
–231,
1998
5
Lassman MN, Genel M, Wise JK, Hendler R, Felig P: Carbohydrate homeostasis and pancreatic islet cell function in thalassemia.
Ann Intern Med
80
:
65
–69,
1974
6
Saudek CD, Hemm RM, Peterson CM: Abnormal glucose tolerance in β-thalassemia major.
Metabolism
26
:
43
–52,
1977
7
Gabutti V, Piga A: Results of long-term iron-chelating therapy.
Acta Haematologica
95
:
26
–36,
1996
8
Arrigo T, Crisafulli G, Meo A, Sturiale M, Lombardo F, Miceli M, Cucinotta D, De Luca F: Glucose tolerance, insulin secretion and peripheral sensitivity in thalassaemia major.
J Pediatr Endocrinol Metab
11(Suppl. 3)
:
863
–866,
1998
9
Gamberini MR, Fortini M, Gilli G, Testa MR, De Sanctis V: Epidemiology and chelation therapy effects on glucose homeostasis in thalassemia patients.
J Pediatr Endocrinol Metab
11(Suppl. 3)
:
867
–869,
1998
10
Italian Working Group on Endocrine Complications in Non-endocrine Diseases: Multicentre study on prevalence of endocrine complications in thalassemia major.
Clin Endocrinol
42
:
581
–586,
1995
11
De Sanctis V, Zurlo MG, Senesi E, Boffa C, Cavallo L, Di Gregorio F: Insulin dependent diabetes in thalassemia.
Arch Dis Child
63
:
58
–62,
1988
12
Merkel PA, Simonson DC, Amiel SA, Plewe G, Sherwin RS, Pearson HA, Tamborlane HA: Insulin resistance and hyperinsulinemia in patients with thalassemia major treated by hypertransfusion.
N Engl J Med
318
:
809
–814,
1988
13
World Health Organization: Diabetes Mellitus: Report of a WHO Study Group. Geneva, World Health Org., 1985 (Tech. Rep. Ser., no. 727)
14
National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance.
Diabetes
28
:
1039
–1057,
1979
15
Ladis V, Theodorides C, Palamidou F, Frissiras S, Berdousi H, Kattamis C: Glucose disturbances and regulation with glibenclamide in thalassemia.
J Pediatr Endocrinol Metab
11(Suppl. 3)
:
871
–878,
1998
16
World Health Organization Expert Committee: Second Report on Diabetes Mellitus. Geneva, World Health Org., 1980 (Tech. Rep. Ser., no. 646)
17
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.
Diabetes Care
20
:
1183
–1197,
1997
18
Holl RW, Buck C, Cario H, Wolf A, Thon A, Kohne E, Debatin K-M: Diagnosis of diabetes in cystic fibrosis and thalassemia major.
Diabetes Care
21
:
671
–672,
1998
19
Ko TM, Hsu PM, Chen CJ, Hsieh FJ, Hsieh CY, Lee TY: Incidence study of heterozygous β-thalassemia in northern Taiwan.
J Formos Med Assoc
88
:
678
–681,
1989
20
Lin KH, Lin LL, Syi S, Lin KS: The incidence of β-thalassemia trait in Taiwan.
Int J Pediatr Oncol
1
:
383
–388,
1994
21
Ko TM, Xu X: Molecular study and prenatal diagnosis of α- and β- thalassemia in Chinese.
J Formos Med Assoc
97
:
5
–15,
1998
22
Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, Allen CJ, Farrell DE, Harris JW: Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major.
N Engl J Med
331
:
567
–573,
1994
23
Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, Martin M, Koren G, Cohen AR: Survival in medically treated patients with homozygous β-thalassemia.
N Engl J Med
331
:
574
–578,
1994
24
Olivieri NF, Brittenham GM: Iron-chelating therapy and the treatment of thalassemia.
Blood
89
:
739
–761,
1997
25
Olivieri NF: The β-thalassemias.
N Engl J Med
341
:
99
–109,
1999
26
Fernandez-Real JM, Ricart-Engel W, Arroyo E, Balanca R, Casamitjana-Abella R, Cabrero D, Fernandez-Castaner M, Soler J: Serum ferritin as a component of the insulin resistance syndrome.
Diabetes Care
21
:
62
–68,
1998
27
Labropoulou-Karatza C, Goritsas C, Fragopanagou H, Repandi M, Matsouka P, Alexandrides T: High prevalence of diabetes mellitus among adult β-thalassemic patients with chronic hepatitis C.
Eur J Gastroenteol Hepatol
11
:
1033
–1036,
1999
28
Kowdley KV, Kaplan MM: Iron-chelation therapy with oral deferiprone: toxicity or lack of efficacy?
N Engl J Med
339
:
468
–469,
1998
29
Piperno A, Fargion S, D’Alba R, Roffi L, Fracanzani AL, Vecchi L, Failla M, Fiorelli G: Liver damage in Italian patients with hereditary hemochromatosis is highly influenced by hepatitis B and C virus infection.
J Hepatol
16
:
364
–368,
1992
30
Dmochowski K, Finegood DT, Francombe W, Tyler B, Zinman B: Factors determining glucose tolerance in patients with thalassemia major.
J Clin Endocrinol Metab
77
:
478
–483,
1993
31
Rahier JR, Loozen S, Goebbels RM, Abrahem M: The haemochromatic human pancreas: a quantitative immunohistochemical and ultrastructural study.
Diabetologia
30
:
5
–12,
1987
32
Costin G, Kogut MD, Hyman C, Ortega JA: Carbohydrate metabolism and pancreatic islet-cell function in thalassemia major.
Diabetes
26
:
230
–240,
1977
33
Lin KH, Lin KS, Feig SA: Marrow transplantation for thalassemia.
Bone Marrow Transplant
1
:
115
–120,
1986
34
Chen YC, Lin KH, Huang WS, Tang JL: Bone marrow transplantation in Taiwan: an overview.
Bone Marrow Transplant
13
:
705
–708,
1994
35
Lin KH, Lin KS: Results of therapy for β-thalassemia major.
J Formos Med Assoc
91
:
126
–130,
1992
36
Cavallo-Perin P, Pacini G, Cerutti F, Bessone A, Condo C, Sacchetti L, Pica A, Pagano G: Insulin resistance and hyperinsulinemia in homozygous β-thalassemia.
Metabolism
44
:
281
–286,
1995

Address correspondence and reprint requests to Kai-Hsin Lin, MD, National Taiwan University Hospital, No. 7, Chungshan S. Rd., Taipei, Taiwan, 10016, R.O.C. E-mail: [email protected].

Received for publication 3 July 2000 and accepted in revised form 18 January 2001.

A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.